entertainment -WSS

entertainment

author：entertainment 2025-10-02 18:47:00 - browse：723

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： CVS is on a mission to consolidate health care. Will it work?

focus

knowledge

WSS

Future doctors need a strong humanities education

Mass General, Mayo Clinic look to monetize custom

WuXi Biologics beefs up its lobbying operation

Mass General, Mayo Clinic look to monetize custom

摘要：有人认为，在线教育现在正像学区房一样悄无声息地成为家长们比拼财富的赛场，甚至是加速着贫富分化。

Update the Apgar Score to remove skin color

focus

entertainment

focus

Walensky prepares to leave CDC — and Congress — behind

The inclusion problem at the heart of rehabilitation research

23andMe had bad news about my health. I wish a person had delivered it

ALS treatment from Biogen, Ionis fails in study

Hepatitis C has a cure — but many Americans still lack access to it

CVS is on a mission to consolidate health care. Will it work?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Dana Farber says 6 studies to be retracted and 31 corrected

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Boston hospital trains restaurant workers on naloxone for overdoses

explore

The inclusion problem at the heart of rehabilitation research

Oak Street deal isn't the answer to health care's woes

Cherokee Nation medical school graduates its first class

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Hottest summer in 2,000 years puts focus on extreme heat, health

focus

knowledge

leisure time

leisure time